Protagonist Therapeutics, Inc - 8-K Filing
Protagonist Therapeutics reports Q3 2026 net income of $220.0 million driven by $275 million in Takeda milestone payments following MIMRYLO FDA approval (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $PTGX